Hepcidin Therapeutics
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Hepcidin is a key hormonal regulator of systemic iron homeostasis and its expression is induced by iron or inflammatory stimuli. Genetic defects in iron signaling to hepcidin lead to “hepcidinopathies” ranging from hereditary hemochromatosis to iron-refractory iron deficiency anemia, which are disorders caused by hepcidin deficiency or excess, respectively. Moreover, dysregulation of hepcidin is a pathogenic cofactor in iron-loading anemias with ineffective erythropoiesis and in anemia of inflammation. Experiments with preclinical animal models provided evidence that restoration of appropriate hepcidin levels can be used for the treatment of these conditions. This fueled the rapidly growing field of hepcidin therapeutics. Several hepcidin agonists and antagonists, as well as inducers and inhibitors of hepcidin expression have been identified to date. Some of them were further developed and are currently being evaluated in clinical trials. This review summarizes the state of the art.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803 · cited 1×
“The binding of hepcidin occludes iron efflux [5] and triggers ubiquitination, internalization and lysosomal degradation of ferroportin [6].”
BackgroundNemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1×
“IL-6 is critical for inflammatory induction of hepcidin, and Il6-/- (IL-6 knockout) mice exhibit an impaired hypoferremic response to acute inflammation [122].”
BackgroundVitamin D metabolism, mechanism of action, and clinical applications
Bikle, D. D. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.12.016 · Cited by 1,933
Adverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
A Red carpet for iron metabolism
Muckenthaler, M. U., Rivella, S., Hentze, M. W., & Galy, B. (2017) · Cell · doi:10.1016/j.cell.2016.12.034 · Cited by 1,319 · cited 2×
“Efficient iron signaling to hepcidin requires auxiliary factors, such as BMP2, the BMP coreceptor hemojuvelin (HJV), the hemochromatosis protein HFE, and the diferric transferrin sensor transferrin receptor 2 (TfR2) [12].”
BackgroundIdentification of erythroferrone as an erythroid regulator of iron metabolism
Kautz, L., Jung, G., Valore, E. V., Rivella, S., Nemeth, E., & Ganz, T. (2014) · Nature Genetics · doi:10.1038/ng.2996 · Cited by 1,127 · cited 3×
“expression is suppressed by erythroferrone (ERFE), a hormone secreted by erythroblasts in response to erythropoietin [23] that neutralizes BMP6 [24].”
BackgroundGanz, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00008.2013 · Cited by 1,122
Papanikolaou, G., & Pantopoulos, K. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.06.021 · Cited by 1,070 · cited 1×
“Accumulation of excess iron in cells is toxic, because “free” ferrous iron catalyzes the generation of hydroxyl radicals via Fenton chemistry, which attack and inactivate cellular macromolecules [1].”
BackgroundSelf-citationPathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease
Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T. (1989) · Blood · doi:10.1182/blood.v74.4.1360.1360 · Cited by 928 · cited 3×
“Castleman disease patients present with iron-refractory hypochromic microcytic anemia, which develops in response to IL-6-mediated upregulation of hepcidin [41].”
BackgroundIron homeostasis in host defence and inflammation
Ganz, T., & Nemeth, E. (2015) · Nature Reviews Immunology · doi:10.1038/nri3863 · Cited by 843 · cited 2×
“On the other hand, BMP6 and HJV are critical components of the inflammatory hepcidin pathway [19,20], which is considered as an innate immune response to depriv i v ding bacteria of iron [21].”
Background
Research works printed but not linked: 103
- Papanikolaou, 2017, Systemic iron homeostasis and erythropoiesis, IUBMB Life, 69, 399, 10.1002/iub.1629 · DOI
- Pandur, 2018, The C19S Substitution Enhances the Stability of Hepcidin While Conserving Its Biological Activity, Protein J., 37, 113, 10.1007/s10930-018-9759-9 · DOI
- Wahedi, 2017, Matriptase-2 suppresses hepcidin expression by cleaving multiple components of the hepcidin induction pathway, J. Biol. Chem., 292, 18354, 10.1074/jbc.M117.801795 · DOI
- Mayeur, 2014, The type I BMP receptor Alk3 is required for the induction of hepatic hepcidin gene expression by interleukin-6, Blood, 123, 2261, 10.1182/blood-2013-02-480095 · DOI · Paper page
- Gineste, 2017, Hepcidin upregulation by inflammation is independent of Smad1/5/8 signaling by activin B, Blood, 129, 533, 10.1182/blood-2016-10-748541 · DOI
- Latour, 2017, Deletion of BMP6 worsens the phenotype of HJV-deficient mice and attenuates hepcidin levels reached after LPS challenge, Blood, 130, 2339, 10.1182/blood-2017-07-795658 · DOI · Paper page
- Fillebeen, 2018, Hepcidin-mediated hypoferremic response to acute inflammation requires a threshold of Bmp6/Hjv/Smad signaling, Blood, 132, 1829, 10.1182/blood-2018-03-841197 · DOI
- Pantopoulos, 2018, Inherited Disorders of Iron Overload, Front. Nutr., 5, 103, 10.3389/fnut.2018.00103 · DOI
- Gupta, 2018, Ineffective Erythropoiesis: Anemia and Iron Overload, Hematol. Oncol. Clin. N. Am., 32, 213, 10.1016/j.hoc.2017.11.009 · DOI · Paper page
- Kowdley, 2016, Iron Overload in Patients with Chronic Liver Disease, Gastroenterol. Hepatol. (N. Y.), 12, 695
- Vela, 2018, Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker, Mol. Med., 24, 5, 10.1186/s10020-018-0008-7 · DOI
- Han, 2016, Hepcidin inhibits Smad3 phosphorylation in hepatic stellate cells by impeding ferroportin-mediated regulation of Akt, Nat. Commun., 7, 13817, 10.1038/ncomms13817 · DOI
- Folgueras, 2018, Matriptase-2 deficiency protects from obesity by modulating iron homeostasis, Nat. Commun., 9, 1350, 10.1038/s41467-018-03853-1 · DOI · Paper page
- Heeney, 2014, Iron-Refractory Iron Deficiency Anemia (IRIDA), Hematol. Oncol. Clin. N. Am., 28, 637, 10.1016/j.hoc.2014.04.009 · DOI
- Fraenkel, 2017, Anemia of Inflammation: A Review, Med. Clin. N. Am., 101, 285, 10.1016/j.mcna.2016.09.005 · DOI · Paper page
- Ueda, 2017, Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond, Curr. Med. Chem., 24, 1417, 10.2174/0929867324666170316120538 · doi:10.2174/0929867324666170316120538
- Nairz, 2016, Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation, Wien. Med. Wochenschr., 166, 411, 10.1007/s10354-016-0505-7 · DOI · Paper page
- You, 2017, Astrocyte hepcidin is a key factor in LPS-induced neuronal apoptosis, Cell Death Dis., 8, e2676, 10.1038/cddis.2017.93 · DOI · Paper page
- Pinnix, 2010, Ferroportin and iron regulation in breast cancer progression and prognosis, Sci. Transl. Med., 2, 43ra56, 10.1126/scitranslmed.3001127 · DOI · Paper page
- Zhou, 2018, E4BP4 promotes thyroid cancer proliferation by modulating iron homeostasis through repression of hepcidin, Cell Death Dis., 9, 987, 10.1038/s41419-018-1001-3 · DOI
- Casu, 2018, Hepcidin agonists as therapeutic tools, Blood, 131, 1790, 10.1182/blood-2017-11-737411 · DOI · Paper page
- Sivakumar, 2016, Management of human factors engineering-associated hemochromatosis: A 2015 update, World J. Hepatol., 8, 395, 10.4254/wjh.v8.i8.395 · DOI
- Niederau, 1985, Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis, N. Engl. J. Med., 313, 1256, 10.1056/NEJM198511143132004 · DOI · Paper page
- Musallam, 2013, Cross-talk between available guidelines for the management of patients with beta-thalassemia major, Acta Haematol., 130, 64, 10.1159/000345734 · DOI
- Besarab, 2010, Iron supplementation to treat anemia in patients with chronic kidney disease, Nat. Rev. Nephrol., 6, 699, 10.1038/nrneph.2010.139 · DOI
- Biggar, 2017, Treatment of renal anemia: Erythropoiesis stimulating agents and beyond, Kidney Res. Clin. Pract., 36, 209, 10.23876/j.krcp.2017.36.3.209 · DOI
- Tzounakas, 2017, Red blood cell transfusion in surgical cancer patients: Targets, risks, mechanistic understanding and further therapeutic opportunities, Transfus. Apheresis Sci., 56, 291, 10.1016/j.transci.2017.05.015 · DOI
- Guo, 2013, Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice, J. Clin. Investig., 123, 1531, 10.1172/JCI66969 · DOI · Paper page
- Casu, 2016, Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia, Haematologica, 101, e8, 10.3324/haematol.2015.133348 · DOI · Paper page
- Aghajan, 2016, Developing a Galnac-Conjugated TMPRSS6 Antisense Therapy for the Treatment of β-Thalassemia, Blood, 128, 1013, 10.1182/blood.V128.22.1013.1013 · doi:10.1182/blood.v128.22.1013.1013
- Schmidt, 2018, RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of beta-thalassemia intermedia, Am. J. Hematol., 93, 745, 10.1002/ajh.25079 · DOI
- Patchen, 2016, Dietary supplementation with ipriflavone decreases hepatic iron stores in wild type mice, Blood Cells Mol. Dis., 60, 36, 10.1016/j.bcmd.2016.05.004 · DOI
- Call, 2017, Imatinib and spironolactone suppress hepcidin expression, Haematologica, 102, 1173, 10.3324/haematol.2016.162917 · DOI
- Zhang, 2016, Icariin regulates systemic iron metabolism by increasing hepatic hepcidin expression through Stat3 and Smad1/5/8 signaling, Int. J. Mol. Med., 37, 1379, 10.3892/ijmm.2016.2545 · DOI
- Bayele, 2015, Phytoestrogens modulate hepcidin expression by Nrf2: Implications for dietary control of iron absorption, Free Radic. Biol. Med., 89, 1192, 10.1016/j.freeradbiomed.2015.11.001 · DOI
- Zhang, 2018, Adenine alleviates iron overload by cAMP/PKA mediated hepatic hepcidin in mice, J. Cell. Physiol., 233, 7268, 10.1002/jcp.26559 · DOI
- Mendez, 2010, Hepcidin treatment in Hfe−/− mice diminishes plasma iron without affecting erythropoiesis, Eur. J. Clin. Investig., 40, 511, 10.1111/j.1365-2362.2010.02291.x · DOI · Paper page
- Fung, 2015, Thiol-derivatized minihepcidins retain biological activity, Bioorg. Med. Chem. Lett., 25, 763, 10.1016/j.bmcl.2014.12.094 · DOI
- Lunova, 2017, Hepcidin knockout mice spontaneously develop chronic pancreatitis owing to cytoplasmic iron overload in acinar cells, J. Pathol., 241, 104, 10.1002/path.4822 · DOI
- Chua, 2015, Small cyclic agonists of iron regulatory hormone hepcidin, Bioorg. Med. Chem. Lett., 25, 4961, 10.1016/j.bmcl.2015.03.012 · DOI
- Lal, A., Piga, A., Viprakasit, V., Maynard, J., Kattamis, A., Yaeger, D., Byrnes, B., Chawla, L., and Tidmarsh, G. (2018, January 14–17). A phase 1, open-label study to determine the safety, tolerability, and pharmacokinetics of escalating doses of LJPC-401 (synthetic human hepcidin) in patients with iron overload. Proceedings of the 23rd European Hematology Association Congress, Stockholm, Sweden. Abstract #S894.
- Bourne, G., Zhao, L., Bhandari, A., Frederick, B., McMahon, J., Tran, V., Annamalai, T., Mattheakis, L., Patel, D., and Smythe, M. (2018, January 14–17). Hepcidin Mimetic PTG-300 for Treatment of Ineffective Erythropoiesis and Chronic Anemia in Hemoglobinopathy Disease. Proceedings of the 23rd European Hematology Association Congress, Stockholm, Sweden. Abstract #S843.
- Nicholls, A., Lickliter, J., Tozzi, L., Liu, D., and Shames, R. (2018, January 14–17). Hepcidin mimetic PTG-300 induces dose-related and sustained reductions in serum iron and transferrin saturation in healthy subjects. Proceedings of the 23rd European Hematology Association Congress, Stockholm, Sweden. Abstract #S895.
- Abreu, 2018, Heparin inhibits intracellular Mycobacterium tuberculosis bacterial replication by reducing iron levels in human macrophages, Sci. Rep., 8, 7296, 10.1038/s41598-018-25480-y · DOI
- Poli, 2014, Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo, Blood, 123, 1564, 10.1182/blood-2013-07-515221 · DOI · Paper page
- Poli, 2014, Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo, Biochem. Pharmacol., 92, 467, 10.1016/j.bcp.2014.09.007 · DOI
- Seldin, 2014, Metabolic function of the CTRP family of hormones, Rev. Endocr. Metab. Disord., 15, 111, 10.1007/s11154-013-9255-7 · DOI · Paper page
- Babitt, 2007, Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance, J. Clin. Investig., 117, 1933, 10.1172/JCI31342 · DOI · Paper page
- Kovac, 2016, Anti-hemojuvelin antibody corrects anemia caused by inappropriately high hepcidin levels, Haematologica, 101, e173, 10.3324/haematol.2015.140772 · DOI · Paper page
- Yu, 2008, Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism, Nat. Chem. Biol., 4, 33, 10.1038/nchembio.2007.54 · DOI · Paper page
- Kanamori, 2016, Regulation of hepcidin expression by inflammation-induced activin B, Sci. Rep., 6, 38702, 10.1038/srep38702 · DOI
- Vogt, 2011, The specificities of small molecule inhibitors of the TGFss and BMP pathways, Cell. Signal., 23, 1831, 10.1016/j.cellsig.2011.06.019 · DOI · Paper page
- Mohedas, 2013, Development of an ALK2-biased BMP type I receptor kinase inhibitor, ACS Chem. Biol., 8, 1291, 10.1021/cb300655w · DOI · Paper page
- Mu, 2016, The dietary flavonoid myricetin regulates iron homeostasis by suppressing hepcidin expression, J. Nutr. Biochem., 30, 53, 10.1016/j.jnutbio.2015.10.015 · DOI
- Fukuda, 2017, Synthesis and SAR studies of 3,6-disubstituted indazole derivatives as potent hepcidin production inhibitors, Bioorg. Med. Chem. Lett., 27, 2148, 10.1016/j.bmcl.2017.03.056 · DOI
- Fukuda, 2017, Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives, Bioorg. Med. Chem. Lett., 27, 5252, 10.1016/j.bmcl.2017.10.031 · DOI
- Fukuda, 2017, Discovery of DS79182026: A potent orally active hepcidin production inhibitor, Bioorg. Med. Chem. Lett., 27, 3716, 10.1016/j.bmcl.2017.07.004 · DOI
- Sasaki, 2018, Target identification of hepcidin production inhibitors by a combination of chemical proteomics and radioactive compound binding assay, Biochem. Biophys. Res. Commun., 503, 2878, 10.1016/j.bbrc.2018.08.061 · DOI
- Peterson, 2016, The ALK-2 Inhibitor, TP-0184, Demonstrates High Distribution to the Liver Contributing to Significant Preclinical Efficacy in Mouse Models of Anemia of Chronic Disease (Abstract), Blood, 128, 263, 10.1182/blood.V128.22.263.263 · DOI
- Pardanani, 2013, Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis, Leukemia, 27, 1322, 10.1038/leu.2013.71 · DOI · Paper page
- Kuhrt, 2015, Emerging EPO and EPO receptor regulators and signal transducers, Blood, 125, 3536, 10.1182/blood-2014-11-575357 · DOI · Paper page
- Asshoff, 2017, Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents, Blood, 129, 1823, 10.1182/blood-2016-09-740092 · DOI · Paper page
- Jones, 2010, Tocilizumab: A review of its safety and efficacy in rheumatoid arthritis, Clin. Med. Insights Arthritis Musculoskelet. Disord., 3, 81, 10.4137/CMAMD.S4864 · DOI
- Song, 2013, Comparative evaluation of the effects of treatment with tocilizumab and TNF-alpha inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients, Arthritis Res. Ther., 15, R141, 10.1186/ar4323 · DOI · Paper page
- Suzuki, 2017, Hepcidin-25 gives an indication of the therapeutic effectiveness of tocilizumab in rheumatoid arthritis—Relationship between disease activity of rheumatoid arthritis and anemia, Rev. Bras. Reumatol. Engl. Ed., 57, 637, 10.1016/j.rbr.2016.07.004 · DOI
- Noguchi-Sasaki, M., Sasaki, Y., Shimonaka, Y., Mori, K., and Fujimoto-Ouchi, K. (2016). Treatment with anti-IL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6-producing lung carcinoma cells. BMC Cancer, 16. · DOI
- Laine, 2017, Curcuma decreases serum hepcidin levels in healthy volunteers: A placebo-controlled, randomized, double-blind, cross-over study, Fundam. Clin. Pharmacol., 31, 567, 10.1111/fcp.12288 · DOI
- Li, W.Y., Li, F.M., Zhou, Y.F., Wen, Z.M., Ma, J., Ya, K., and Qian, Z.M. (2016). Aspirin down Regulates Hepcidin by Inhibiting NF-kappaB and IL6/JAK2/STAT3 Pathways in BV-2 Microglial Cells Treated with Lipopolysaccharide. Int. J. Mol. Sci., 17. · DOI
- Huang, 2018, Aspirin increases ferroportin 1 expression by inhibiting hepcidin via the JAK/STAT3 pathway in interleukin 6-treated PC-12 cells, Neurosci. Lett., 662, 1, 10.1016/j.neulet.2017.10.001 · DOI
- Marcon, 2013, Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis, J. Immunol., 191, 4288, 10.4049/jimmunol.1202743 · DOI · Paper page
- Wang, 2016, Maresin 1 ameliorates iron-deficient anemia in IL-10(−/−) mice with spontaneous colitis by the inhibition of hepcidin expression though the IL-6/STAT3 pathway, Am. J. Transl. Res., 8, 2758
- Liu, 2012, Polysaccharide isolated from Angelica sinensis inhibits hepcidin expression in rats with iron deficiency anemia, J. Med. Food, 15, 923, 10.1089/jmf.2012.2231 · DOI
- Wang, 2017, Acidic Polysaccharide from Angelica sinensis Reverses Anemia of Chronic Disease Involving the Suppression of Inflammatory Hepcidin and NF-kappaB Activation, Oxid. Med. Cell. Longev., 2017, 7601592, 10.1155/2017/7601592 · DOI
- Wang, 2018, Correction of Anemia in Chronic Kidney Disease with Angelica sinensis Polysaccharide via Restoring EPO Production and Improving Iron Availability, Front. Pharmacol., 9, 803, 10.3389/fphar.2018.00803 · DOI
- Olas, 2015, Hydrogen sulfide in signaling pathways, Clin. Chim. Acta, 439, 212, 10.1016/j.cca.2014.10.037 · DOI · Paper page
- Xin, 2016, Hydrogen Sulfide Attenuates Inflammatory Hepcidin by Reducing IL-6 Secretion and Promoting SIRT1-Mediated STAT3 Deacetylation, Antioxid. Redox Signal., 24, 70, 10.1089/ars.2015.6315 · DOI
- Wang, M., Tang, W., Xin, H., and Zhu, Y.Z. (2016). S-Propargyl-Cysteine, a Novel Hydrogen Sulfide Donor, Inhibits Inflammatory Hepcidin and Relieves Anemia of Inflammation by Inhibiting IL-6/STAT3 Pathway. PLoS ONE, 11. · DOI
- Wang, 2017, AMPK Serves as a Therapeutic Target Against Anemia of Inflammation, Antioxid. Redox Signal., 27, 251, 10.1089/ars.2016.6846 · DOI
- Angmo, 2017, Identification of Guanosine 5′-diphosphate as Potential Iron Mobilizer: Preventing the Hepcidin-Ferroportin Interaction and Modulating the Interleukin-6/Stat-3 Pathway, Sci. Rep., 7, 40097, 10.1038/srep40097 · DOI
- Guo, 2013, Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells, Aging Cell, 12, 280, 10.1111/acel.12052 · DOI · Paper page
- Ohlander, 2018, Erythrocytosis Following Testosterone Therapy, Sex. Med. Rev., 6, 77, 10.1016/j.sxmr.2017.04.001 · DOI · Paper page
- Guo, 2016, Effects of Testosterone on Erythropoiesis in a Female Mouse Model of Anemia of Inflammation, Endocrinology, 157, 2937, 10.1210/en.2016-1150 · DOI
- Bachman, 2014, Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: Evidence for a new erythropoietin/hemoglobin set point, J. Gerontol. A Biol. Sci. Med. Sci., 69, 725, 10.1093/gerona/glt154 · DOI · Paper page
- Beggs, 2014, Testosterone alters iron metabolism and stimulates red blood cell production independently of dihydrotestosterone, Am. J. Physiol. Endocrinol. Metab., 307, E456, 10.1152/ajpendo.00184.2014 · DOI
- Dhindsa, 2016, Effect of testosterone on hepcidin, ferroportin, ferritin and iron binding capacity in patients with hypogonadotropic hypogonadism and type 2 diabetes, Clin. Endocrinol. (Oxf.), 85, 772, 10.1111/cen.13130 · DOI
- Gagliano-Juca, T., Pencina, K.M., Ganz, T., Travison, T.G., Kantoff, P.W., Nguyen, P.L., Taplin, M.E., Kibel, A.S., Li, Z., and Huang, G. (2018). Mechanisms Responsible for Reduced Erythropoiesis during Androgen Deprivation Therapy in Men with Prostate Cancer. Am. J. Physiol. Endocrinol. Metab. · DOI
- Lehtihet, M., Bonde, Y., Beckman, L., Berinder, K., Hoybye, C., Rudling, M., Sloan, J.H., Konrad, R.J., and Angelin, B. (2016). Circulating Hepcidin-25 Is Reduced by Endogenous Estrogen in Humans. PLoS ONE, 11. · DOI · Paper page
- Bajbouj, 2018, Elevated Levels of Estrogen Suppress Hepcidin Synthesis and Enhance Serum Iron Availability in Premenopausal Women, Exp. Clin. Endocrinol. Diabetes, 126, 453, 10.1055/s-0043-124077 · DOI
- Smith, 2015, Vitamin D and anemia: Insights into an emerging association, Curr. Opin. Endocrinol. Diabetes Obes., 22, 432, 10.1097/MED.0000000000000199 · DOI · Paper page
- Smith, 2017, High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults, Clin. Nutr., 36, 980, 10.1016/j.clnu.2016.06.015 · DOI · Paper page
- Smith, 2018, High-Dose Vitamin D3 Administration Is Associated with Increases in Hemoglobin Concentrations in Mechanically Ventilated Critically Ill Adults: A Pilot Double-Blind, Randomized, Placebo-Controlled Trial, JPEN J. Parenter. Enter. Nutr., 42, 87, 10.1177/0148607116678197 · DOI
- Atkinson, 2017, Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial, Pediatr. Nephrol., 32, 859, 10.1007/s00467-016-3563-6 · DOI
- Panwar, B., McCann, D., Olbina, G., Westerman, M., and Gutierrez, O.M. (2018). Effect of calcitriol on serum hepcidin in individuals with chronic kidney disease: A randomized controlled trial. BMC Nephrol., 19. · DOI
- Cooke, 2013, A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates, Blood, 122, 3054, 10.1182/blood-2013-06-505792 · DOI · Paper page
- Krzyzanski, 2016, Pharmacodynamic Model of Hepcidin Regulation of Iron Homeostasis in Cynomolgus Monkeys, AAPS J., 18, 713, 10.1208/s12248-016-9886-1 · DOI
- Abonour, 2017, A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia, J. Hematol. Oncol., 10, 73, 10.1186/s13045-017-0427-x · DOI · Paper page
- Rothe, 2018, Anticalin((R)) Proteins as Therapeutic Agents in Human Diseases, BioDrugs, 32, 233, 10.1007/s40259-018-0278-1 · DOI
- Veronese, 2008, The impact of PEGylation on biological therapies, BioDrugs, 22, 315, 10.2165/00063030-200822050-00004 · DOI · Paper page
- Vater, 2015, Turning mirror-image oligonucleotides into drugs: The evolution of Spiegelmer((R)) therapeutics, Drug Discov. Today, 20, 147, 10.1016/j.drudis.2014.09.004 · DOI · Paper page
- Boyce, 2016, Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects, Br. J. Pharmacol., 173, 1580, 10.1111/bph.13433 · DOI · Paper page
- Macdougall, I.C., Rumjon, A., Cinco, J., Goldstein, L., Summo, L., Vauleon, S., and Riecke, K. (2015). Pharmacokinetics and pharmacodynamics of lexaptepid, a novel anti-hepcidin molecule, in ESA-resistant haemodialysis patients. Nephrol. Dial. Transplant., 20. · doi:10.1093/ndt/gfv182.08
- Georgiev, P., Lazaroiu, M., Ocroteala, L., Grudeva-Popova, J., Gheorghita, E., Vasilica, M., Popescu, S.M., Cucuianu, A., Summo, L., and Schwoebel, F. (2014). The anti-hepcidin Spiegelmer® Lexaptepid Pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: A phase II pilot study. Cancer Res., 74. · DOI
- Barrington, 2016, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Anti-Ferroportin Antibody in Patients with Anemia Due to Chronic Renal Failure (Abstract), Blood, 128, 1280, 10.1182/blood.V128.22.1280.1280 · DOI
Cited by
Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Targeting ferroptosis opens new avenues for the development of novel therapeutics
Sun, S., Shen, J., Jiang, J., Wang, F., & Min, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01606-1 · Cited by 608
Hepcidin and Iron in Health and Disease
Nemeth, E., & Ganz, T. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-032816 · Cited by 457
Charlebois, E., Fillebeen, C., Katsarou, A., Rabinovich, A., Wisniewski, K., Venkataramani, V., Michalke, B., Velentza, A., & Pantopoulos, K. (2022) · eLife · doi:10.7554/elife.81332 · Cited by 22
Self-citation
Metadata
- Authors
- Katsarou, A., & Pantopoulos, K.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2018-11-21
- Volume
- 11
- Issue
- 4
- Pages
- 127
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W4229492953
- Cited by
- 112
- References
- 79
- FWCI
- 6.23
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Canadian Institutes of Health Research (PJT-159730)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.